Boston Globe Op-Eds Examine Conflict-of-Interest Policies At Medical Journals, FDA
David Shaywitz: The argument that "drug company money will bias the conclusions of otherwise trustworthy university scientists" is a "dangerous sham -- a sham because it derives from a naïve preconception about the purity of academic scientists, and dangerous, because by discouraging collaborations between researchers from university and industry, we will slow the pace of medical progress," Shaywitz, an endocrinologist at Massachusetts General Hospital, writes in a Globe opinion piece. Shaywitz writes that "the newfound obsession with financial conflicts of interest obscures ... other, often more compelling pressures on university researchers," such as the pressure to produce "attention-getting results." Shaywitz concludes, "Coming up with novel treatments for dreadful diseases is a difficult enough task under the best of circumstances; let's not complicate this mission further by misjudging either the intrinsic virtue of academic scientists or the alleged venality of drug companies; instead, let us learn how to foster productive, transparent collaborations so that the promise of modern science can be realized in the treatment of our patients" (Shaywitz, Boston Globe, 7/27).
"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Boston Globe Op-Eds Examinaþi conflictul de Interes Politici medicale Jurnale, FDA - Boston Globe Op-Eds Examine Conflict-of-Interest Policies At Medical Journals, FDA - articole medicale engleza - startsanatate